Sichuan Baili Pharmaceutical Co., Ltd.

This study tests a new drug called BL-B01D1 against standard treatments for people with advanced bile duct cancer that has worsened after chemotherapy and immunotherapy. About 538 adults will be randomly assigned to receive either the new drug or a doctor-chosen treatment. The ma…

This study tests a new drug combination (BL-B01D1 plus tislelizumab) against standard chemotherapy plus tislelizumab as the first treatment for people with extensive-stage small cell lung cancer. About 562 adults with this advanced cancer will take part. The goal is to see if the…

This early-phase study tests a new drug called BL-ARC002 in 22 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants receive the drug at d…

This study tests an experimental drug called BL-M11D1 in about 92 adults with a type of blood cancer (myelodysplastic syndromes) that has come back or stopped responding to treatment. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must be 18-7…

This study tests a new drug called BL-M07D1 against standard chemotherapy in people with HER2-positive ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 404 adults aged 18-75 will be randomly assigned to receive either BL…

This study tests a new drug called BL-M11D1 combined with standard chemotherapy or other targeted drugs for adults with newly diagnosed acute myeloid leukemia (AML). The goal is to see if the combination is safe and helps more patients achieve remission. About 216 participants wi…

This study tests a new drug, BL-B01D1, combined with tislelizumab (with or without 5-FU) against standard chemotherapy plus tislelizumab for people with advanced esophageal cancer that cannot be removed by surgery. About 90 adults will participate. The goal is to see if the new c…

This early-stage study tests a new drug called BL-M24D1 in about 33 people whose multiple myeloma or other blood cancer has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors.…

This study tests a new drug called BL-M05D1 in people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and has stopped responding to initial treatment. About 438 adults will be randomly assigned to receive either BL-M05D1 or a standa…

This phase 3 trial tests a new drug, BL-M07D1, combined with pertuzumab against the standard treatment (docetaxel, trastuzumab, and pertuzumab) in 596 women with HER2-positive breast cancer that has spread or returned. The goal is to see if the new combo delays cancer growth or i…